StockMacro
Company, fund or insider

Help

Menu

Palvella Therapeutics

$142.85 +21% in 6 monthsMarket cap $2.1B

PVLA on XNAS, Health Care, Palvella Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 56% in a year but short interest is 18% of shares and insiders sold $11.1M.

  • WatchCash $236.7M against a $75M net loss over 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Industry
Pharmaceutical preparations (Health Care)
Employees
29
Website
palvellatx.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 23 Feb 2027 (an estimate: a year ago it reported on 24 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $24.6M.
Quarter to 31 Dec 2021: revenue $8.4M, net income -$9.5MQuarter to 31 Dec 2021: revenue $8.4M, net income -$9.5MQuarter to 31 Mar 2022: revenue $11.2M, net income -$5.1MQuarter to 31 Mar 2022: revenue $11.2M, net income -$5.1MQuarter to 30 Jun 2022: revenue $3.7M, net income -$10.3MQuarter to 30 Jun 2022: revenue $3.7M, net income -$10.3MQuarter to 30 Sep 2022: revenue $5.4M, net income -$9.7MQuarter to 30 Sep 2022: revenue $5.4M, net income -$9.7MQuarter to 31 Dec 2022: revenue $5.8M, net income -$8.1MQuarter to 31 Dec 2022: revenue $5.8M, net income -$8.1MQuarter to 31 Mar 2023: revenue $2.0M, net income -$13.2MQuarter to 31 Mar 2023: revenue $2.0M, net income -$13.2MQuarter to 30 Jun 2023: revenue $20.1M, net income $4.0MQuarter to 30 Jun 2023: revenue $20.1M, net income $4.0MQuarter to 30 Sep 2023: revenue $19.5M, net income -$10.8MQuarter to 30 Sep 2023: revenue $19.5M, net income -$10.8MQuarter to 31 Dec 2023: revenue –, net income -$4.6MQuarter to 31 Mar 2024: revenue $53K, net income -$4.9MQuarter to 31 Mar 2024: revenue $53K, net income -$4.9MQuarter to 30 Jun 2024: revenue $0, net income -$3.6MQuarter to 30 Jun 2024: revenue $0, net income -$3.6MQuarter to 30 Sep 2024: revenue $0, net income -$2.9MQuarter to 30 Sep 2024: revenue $0, net income -$2.9MQuarter to 31 Mar 2025: revenue –, net income -$8.2MQuarter to 30 Jun 2025: revenue –, net income -$9.5MQuarter to 30 Sep 2025: revenue –, net income -$11.3MQuarter to 31 Dec 2025: revenue –, net income -$12.7MQuarter to 31 Mar 2026: revenue –, net income -$15.8MQuarter to 30 Jun 2026: revenue –, net income -$21.9MQuarter to 30 Sep 2026: revenue –, net income -$24.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $24.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$24.6M
30 Jun 2026–-$21.9M
31 Mar 2026–-$15.8M
31 Dec 2025–-$12.7M
30 Sep 2025–-$11.3M
30 Jun 2025–-$9.5M
31 Mar 2025–-$8.2M
30 Sep 2024$0-$2.9M
30 Jun 2024$0-$3.6M
31 Mar 2024$53K-$4.9M
31 Dec 2023–-$4.6M
30 Sep 2023$19.5M-$10.8M
30 Jun 2023$20.1M$4.0M
31 Mar 2023$2.0M-$13.2M
31 Dec 2022$5.8M-$8.1M
30 Sep 2022$5.4M-$9.7M
30 Jun 2022$3.7M-$10.3M
31 Mar 2022$11.2M-$5.1M
31 Dec 2021$8.4M-$9.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$75.0M -$33.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$5.50 -$1.62
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -63.4% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $236.7M $63.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$236.7M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $13.54
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 10.6 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Palvella TherapeuticsPVLA (this company) $2.1Bloss–––
NewAmsterdam PharmaNAMS $2.2Bloss85.1-26%-790%
PerrigoPRGO $2.2Bloss0.54-4.5%-43.3%
Aurinia PharmaceuticalsAUPH $2.0B6.36.1+21%97.7%
Arcus BiosciencesRCUS $2.2Bloss22.5-58%-453%
Harmony BiosciencesHRMY $1.9B10.71.9+20%18.1%

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$11.1M

bought $0, sold $11.1M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

0%

196 13F filers vs 196

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

100%

14.6M shares held by 13F filers (30 Sep 2026) of 14.6M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

18%

2.6M shares sold short (30 Oct 2026) of 14.6M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

11.5

2.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+8.1%

2.4M shares sold short in the report before, 2.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

54%

54% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 65%

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$649K

the 12 months before: $480K

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

16

16 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.0×

16 articles in the last 7 days; its usual week has 2.

Price $142.85 on 20 Nov 2026, +56% over 12 months (12-month range $76.43 to $175.92)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $14.7M in the last 12 months (the 12 months before: -$218K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.
Capital spending per quarter. Capital spending $0 in the latest quarter, -100% on a year earlier.
Institutional holders (13F filers). 196 13F filers reported holding it in the latest 13F quarter, +100% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months, -100% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
30 Jun 20268-K and other filingsDirector or officer change
16 Jun 20268-K and other filingsDirector or officer change
13 Apr 20268-K and other filingsDirector or officer change
13 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Jan 20258-K and other filingsRegistered new securities for sale (S-1)
31 Dec 20248-K and other filingsRegistered new securities for sale (S-1)
14 Dec 20248-K and other filingsDirector or officer change
14 Dec 20248-K and other filingsCompleted an acquisition or asset sale
12 Dec 20248-K and other filingsDirector or officer change
12 Dec 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
24 Jul 20248-K and other filingsDirector or officer change
24 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Jul 20248-K and other filingsA major agreement ended
21 Dec 20238-K and other filingsA major agreement ended
15 Aug 2023Sharp changeQuarterly revenue change: quarterly revenue change, 20.1M vs usual 4.3M (2023-06-30); 5.8x the same period a year earlier
18 Jul 20238-K and other filingsRestructuring costs announced
18 Jul 20238-K and other filingsA major agreement ended
13 Jul 20238-K and other filingsDirector or officer change
26 Jun 20238-K and other filingsDirector or officer change
26 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 May 20238-K and other filingsDelisting notice or listing transfer
4 Aug 20228-K and other filingsDirector or officer change
24 Jun 20228-K and other filingsDirector or officer change
24 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 May 2022: $10K published
Month from 1 May 2023: $8K published
Month from 1 Aug 2024: $92K published
Month from 1 Oct 2024: $1 published
Month from 1 Dec 2024: $52K published
Month from 1 Apr 2025: $101K published
Month from 1 Nov 2025: -$371K published
Month from 1 Dec 2025: -$415K published
Month from 1 Jan 2026: -$420K published
Month from 1 Feb 2026: -$342K published
Month from 1 Mar 2026: $292K published
Month from 1 Apr 2026: -$497K published
Month from 1 May 2026: -$476K published
Month from 1 Jun 2026: -$476K published
Month from 1 Jul 2026: -$642K published
Month from 1 Aug 2026: -$655K published
Month from 1 Sep 2026: -$4.9M published
Month from 1 Oct 2026: -$4.1M published
Month from 1 Nov 2026: -$2.1M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2025: 2 published
Revenue per quarter
Quarter ended 31 Dec 2021: $8.4M, +350% on a year earlier; public on 3 Mar 2022
Quarter ended 31 Mar 2022: $11.2M, -28% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $3.7M, +13% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $5.4M, +32% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $5.8M, -31% on a year earlier; public on 1 Apr 2023
Quarter ended 31 Mar 2023: $2.0M, -82% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $20.1M, +443% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $19.5M, +264% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Mar 2024: $53K, -97% on a year earlier; public on 16 May 2024
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 14 Nov 2024
Capital spending per quarter
Quarter ended 31 Dec 2021: $342K, -41% on a year earlier; public on 3 Mar 2022
Quarter ended 31 Mar 2022: $389K, +1289% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $629K, +175% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $34K, -90% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Mar 2023: $48K, -88% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $67K, -89% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $69K, +103% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 16 May 2024
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 14 Nov 2024
Institutional holders (13F filers)
31 Dec 2024 report: 32; public on 14 Feb 2025
31 Mar 2025 report: 40; public on 15 May 2025
30 Jun 2025 report: 63; public on 14 Aug 2025
30 Sep 2025 report: 98; public on 14 Nov 2025
31 Dec 2025 report: 136; public on 17 Feb 2026
31 Mar 2026 report: 178; public on 15 May 2026
30 Jun 2026 report: 196; public on 14 Aug 2026
30 Sep 2026 report: 196; public on 16 Nov 2026
Federal obligations
Month from 1 Oct 2024: $480K published
Month from 1 Sep 2025: $649K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $2.1M (12 Nov 2026), 3.8× its normal reading; higher than 86% of its own history.
  • Insider net buying (open market): Insiders sold a net $14.7M in the last 12 months (the 12 months before: -$218K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
  • Revenue per quarter: Revenue $0 in the latest quarter, -100% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 39 insider trades

Last 90 days: 6 sales, $11.1M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Nov 2026Jeffrey S MartiniChief Scientific OfficerSellplanned in advance (10b5-1); after exercising options12,500$166.65$2.1MForm 4
23 Oct 2026Kathleen GoinChief Operating OfficerSellplanned in advance (10b5-1); after exercising options4,313$124.58$537KForm 4
14 Oct 2026George M JenkinsDirectorSellplanned in advance (10b5-1)27,500$130.16$3.6MForm 4
18 Sep 2026Kathleen GoinChief Operating OfficerSellplanned in advance (10b5-1); after exercising options4,302$152.24$655KForm 4
15 Sep 2026George M JenkinsDirectorSellplanned in advance (10b5-1)27,500$151.53$4.2MForm 4
4 Sep 2026Christopher P KiritsyDirectorSellafter exercising options313$157.00$49KForm 4
20 Aug 2026Kathleen GoinChief Operating OfficerSellplanned in advance (10b5-1); after exercising options4,302$152.21$655KForm 4
17 Jul 2026Kathleen GoinChief Operating OfficerSellplanned in advance (10b5-1); after exercising options4,302$149.28$642KForm 4

196 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 27 opened a position, 26 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Jennison Associates LLC1.1M7.54%$152.0M+141K+15%
Montanova Capital, LLC1.0M7.15%$144.1M-91K-8.0%
BlackRock, Inc.990K6.77%$136.5M+71K+7.8%
Frazier Life Sciences Management, L.P.882K6.04%$121.7MNo change
First Light Asset Management, LLC734K5.02%$101.3M-38K-4.9%
State Street Corp625K4.27%$86.2M-28K-4.3%
BVF Inc607K4.15%$83.7M-66K-9.8%
T. Rowe Price Associates Inc592K4.05%-47K-7.3%
Vanguard Capital Management LLC541K3.70%$74.6M+27K+5.2%
Westfield Capital Management Co LP396K2.71%$54.6MNew+396K

Company events

All 65 company events

In 12 months: 3 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
30 Jun 2026Director or officer change8-K
16 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
13 Apr 2026Director or officer change8-K
26 Feb 2026Signed a major agreement8-K
14 Jan 2025Registered new securities for sale (S-1)S-1/A
31 Dec 2024Registered new securities for sale (S-1)S-1
13 Dec 2024Director or officer change; Signed a major agreement; Completed an acquisition or asset saleSame filing: sold shares privately, changed shareholder rights, change of control, changed its bylaws or fiscal year8-K
12 Dec 2024Director or officer changeSame filing: changed shareholder rights, changed its bylaws or fiscal year, shareholder vote results8-K

The 5 newest of 95 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 30 Jun 2026Filings record

    Director or officer change

  2. 16 Jun 2026Filings record

    Director or officer change

  3. 13 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 13 Apr 2026Filings record

    Director or officer change

  5. 2 Apr 2026Insiders record

    JENKINS GEORGE M (director) bought 445 shares of PVLA ($49,974) (dated 1 Apr 2026)

  6. 3 Mar 2026Insiders record

    HERON ELAINE J (director) bought 2,400 shares of PVLA ($300,000) (dated 2 Mar 2026)

  7. 3 Mar 2026Insiders record

    JENKINS GEORGE M (director) bought 4,000 shares of PVLA ($500,000) (dated 2 Mar 2026)

  8. 11 Apr 2025Insiders record

    JENKINS GEORGE M (director) bought 4,990 shares of PVLA ($100,797) (dated 10 Apr 2025)

  9. 14 Jan 2025Filings record

    Registered new securities for sale (S-1)

  10. 31 Dec 2024Filings record

    Registered new securities for sale (S-1)

  11. 20 Dec 2024Insiders record

    JENKINS GEORGE M (director) bought 4,000 shares of PVLA ($51,720) (dated 19 Dec 2024)

  12. 14 Dec 2024Filings record

    Director or officer change (dated 13 Dec 2024)

  13. 14 Dec 2024Filings record

    Completed an acquisition or asset sale (dated 13 Dec 2024)

  14. 12 Dec 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 12 Dec 2024Filings record

    Director or officer change

  16. 29 Oct 2024Insiders record

    GERAGHTY JAMES A (director) bought 1 shares of PIRS ($1) (dated 28 Oct 2024)

  17. 13 Aug 2024Insiders record

    ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 6,000 shares of PIRS ($92,310) (dated 12 Aug 2024)

  18. 24 Jul 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 24 Jul 2024Filings record

    Director or officer change

  20. 3 Jul 2024Filings record

    A major agreement ended

  21. 21 Dec 2023Filings record

    A major agreement ended

  22. 15 Aug 2023Financials change

    reported revenue of $20.1M for the quarter ended 30 Jun 2023, 5.8× the same quarter last year.

    Same quarter last year: $3.5M; its normal quarter is $4.3M.

    See the evidence
    This period
    $20.1M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $4.3M
    Typical spread (median absolute deviation)
    $1.6M
    How far from its usual level
    +6.5
    Same quarter last year
    $3.5M
    History used
    3,560 days
    2021-06-30: $2.5M2021-09-30: $2.8M2021-12-31: $7.8M2022-03-31: $11.2M2022-06-30: $3.5M2022-09-30: $5.1M2022-12-31: $5.7M2023-03-31: $2.0M2023-06-30: $20.1M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $4.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 18 Jul 2023Filings record

    Restructuring costs announced

  24. 18 Jul 2023Filings record

    A major agreement ended

  25. 13 Jul 2023Filings record

    Director or officer change

  26. 26 Jun 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 26 Jun 2023Filings record

    Director or officer change

  28. 31 May 2023Insiders record

    KIRITSY CHRISTOPHER P (director) bought 10,000 shares of PIRS ($8,500) (dated 30 May 2023)

  29. 19 May 2023Filings record

    Delisting notice or listing transfer

  30. 4 Aug 2022Filings record

    Director or officer change

  31. 24 Jun 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 24 Jun 2022Filings record

    Director or officer change

  33. 17 May 2022Insiders record

    Demuth Tim (Chief Medical Officer) bought 6,000 shares of PIRS ($10,260) (dated 16 May 2022)

  34. 6 Oct 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 6 Oct 2021Filings record

    Director or officer change

  36. 29 Jun 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 29 Jun 2021Filings record

    Director or officer change

  38. 29 Jun 2020Filings record

    Director or officer change

  39. 11 May 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 11 May 2020Filings record

    Director or officer change

Showing the newest 40 of 70 entries; narrow the window or the kind of data to see older ones.

Not listed: 173 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001583648
Ticker
PVLA
Domain
palvellatx.com
Employer name
Palvella Therapeutics, Inc. (1 unverified)
Fein
81-2228053 (1 unverified)
Hq location
PA|WAYNE|19087 (1 unverified)
Name
Marika Inc., Palvella Therapeutics, Inc., PIERIS PHARMACEUTICALS, INC.
Uei
KTH1B7KWRCN9
  • DOL H-1B labor condition applications and PERM certifications5 data points9 Jun 2025 to 9 Jun 2025
  • SEC Form 13F institutional holdings72 data points31 Dec 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)191 records23 Mar 2016 to 19 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)821 data points31 Dec 2012 to 2 Nov 2026
  • SEC Form 4 insider transactions39 records, 140 data points15 Jun 2016 to 12 Nov 2026
  • FINRA short interest (twice monthly)135 data points31 Dec 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)970 data points16 Dec 2024 to 20 Nov 2026
  • USASpending.gov federal awards9 data points20 Sep 2024 to 29 Aug 2025